Sydney Lupkin Sydney Lupkin is the pharmaceuticals correspondent for NPR.
Stories By

Sydney Lupkin

Sydney Lupkin

Pharmaceuticals Correspondent

Sydney Lupkin is the pharmaceuticals correspondent for NPR.

She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.

Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.

Story Archive

Tuesday

After more than 20 years, a major arthritis drug is about to face cheaper competition

  • Download
  • <iframe src="https://www.npr.org/player/embed/1152907937/1152907938" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Thursday

Rapid antigen tests are ubiquitous, but some Americans have learned the hard way that a negative test result isn't necessarily the final word. Mahmoud Illean/AP hide caption

toggle caption
Mahmoud Illean/AP

Is it time for a reality check on rapid COVID tests?

  • Download
  • <iframe src="https://www.npr.org/player/embed/1149672577/1150075892" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Thursday

The Food and Drug Administration announced it has loosened some restrictions on the pill mifepristone, allowing it to be dispensed by more pharmacies and without an in-person exam. Charlie Neibergall/AP hide caption

toggle caption
Charlie Neibergall/AP

Wednesday

Abortion pill could soon become much easier to obtain

  • Download
  • <iframe src="https://www.npr.org/player/embed/1146953383/1146960969" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Thursday

Democrats may make some progress toward lowering high drug prices

  • Download
  • <iframe src="https://www.npr.org/player/embed/1115542020/1115542021" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Monday

Kristi Alcayaga's teenage son, Michael, was able to try a cancer drug called clofarabine that got an accelerated approval from the Food and Drug Administration. But the medicine didn't help him. Jovelle Tamayo for NPR hide caption

toggle caption
Jovelle Tamayo for NPR

Friday

Kristi Alcayaga's teenage son, Michael, was able to try a cancer drug called clofarabine that got an accelerated approval from the Food and Drug Administration. But the medicine didn't help him. Jovelle Tamayo for NPR hide caption

toggle caption
Jovelle Tamayo for NPR

Drugmakers are slow to prove medicines that got a fast track to market really work

  • Download
  • <iframe src="https://www.npr.org/player/embed/1110830985/1112970297" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

EVERETT, WA -­ JUNE 24, 2022: Photos of the late Michael Alcayaga, Kristi Alcayaga's son, with his three siblings at their home on Friday, June 24, 2022, in Everett, Wash. Alcayaga's teenage son, Michael, had leukemia and was able to try a new drug, Clofarabine, through the accelerated approvals process. Michael died on May 20, 2014, a few weeks after his 16th birthday. Jovelle Tamayo/Jovelle Tamayo for NPR hide caption

toggle caption
Jovelle Tamayo/Jovelle Tamayo for NPR

Thursday

Some fast-tracked drugs are tardy doing their trials to get regular FDA approval

  • Download
  • <iframe src="https://www.npr.org/player/embed/1112777674/1112777675" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Wednesday

2 House subcommittees are trying to get answers about the baby formula shortage

  • Download
  • <iframe src="https://www.npr.org/player/embed/1101307685/1101307738" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Thursday

White House invokes the Defense Production Act for the baby formula shortage

  • Download
  • <iframe src="https://www.npr.org/player/embed/1099997239/1099997240" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Tuesday

Paxlovid tablets are packaged at a Pfizer factory in Italy. Pfizer hide caption

toggle caption
Pfizer

Feds' contract with Pfizer for Paxlovid has some surprises

  • Download
  • <iframe src="https://www.npr.org/player/embed/1075876794/1077371694" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Friday

Biden promised a billion COVID tests. Contracts to buy them are being announced

  • Download
  • <iframe src="https://www.npr.org/player/embed/1073215447/1073215448" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Friday

Thomas Hansmann/Pfizer

The COVID antiviral drugs are here but they're scarce. Here's what to know

  • Download
  • <iframe src="https://www.npr.org/player/embed/1069323181/1069739439" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript